Oncosil Medical Reports Positive Cash Flow of $5.53m for the March 2018 Quarter

OncoSil Medical Ltd, a medical device company focused on localised treatments for patients with pancreatic and liver cancer, today released its Appendix 4C – Quarterly Cashflow report for the quarter ended 31 March 2018 (the Quarter or 3Q 18). All financial results are in Australian dollars and are unaudited.

Key highlights

  • Highly encouraging progress in Global Clinical Study over the past quarter.
  • 5 of the initial 20 study participants have undergone surgical resection with curative intent
  • 44 patients now enrolled in PanCO clinical study, with 33 successful implants completed to date with the OncoSil™ device and strong clinical performance achieved across multiple metrics
  • First study participants in the US and in Belgium successfully implanted with the OncoSil™ device as screening and recruitment efforts in both geographies continue to progress
  • 3 US patients now enrolled in OncoPaC-1
  • Successful completion of oversubscribed institutional placement, raising approximately $12.7 million, and oversubscribed Share Purchase Plan (SPP), raising approximately $4.0 million
  • Receipt of additional $0.6 million from R&D Tax Incentive Refund
  • Cash balance as at 31 March 2018 of $10.7m

OncoSil Chief Executive Officer, Daniel Kenny commented:

“We are very pleased with our progress over this last quarter. The emerging outcomes and results from our Global Pancreatic Clinical Study Programme are highly encouraging. We anticipate submitting 16-week data for the first 20 patients to the EU Notified Body, BSI by the end of May.

“We are particularly excited to have observed surgical resection outcomes in 5 out of the first 20 implanted patients in the study. This is an important achievement as it demonstrates the potential of the OncoSil™ device, in combination with chemotherapy, to take these patient’s tumours from an inoperable to operable state which is a significantly improved outcome.

“We were pleased with the strong support from our shareholders to our recent capital raising and look forward to continuing our plans to commercialise the breakthrough OncoSil™ treatment.”


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s